Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Rating of “Moderate Buy” from Brokerages

Outlook Therapeutics, Inc. (NASDAQ:OTLK) has been given a consensus rating of “Moderate Buy” by the seven analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $28.07.

A number of equities analysts have issued reports on the company. Chardan Capital restated a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. BTIG Research decreased their price target on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a research note on Friday, November 29th. Guggenheim reaffirmed a “buy” rating and set a $12.00 price target on shares of Outlook Therapeutics in a research note on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday.

Institutional Investors Weigh In On Outlook Therapeutics

Several large investors have recently made changes to their positions in the business. Great Point Partners LLC grew its position in Outlook Therapeutics by 15.0% during the second quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock valued at $12,557,000 after buying an additional 221,510 shares during the period. Squarepoint Ops LLC bought a new position in shares of Outlook Therapeutics during the 2nd quarter valued at approximately $232,000. AQR Capital Management LLC bought a new stake in shares of Outlook Therapeutics in the 2nd quarter worth approximately $75,000. Susquehanna Fundamental Investments LLC purchased a new position in Outlook Therapeutics in the second quarter valued at approximately $303,000. Finally, Christensen King & Associates Investment Services Inc. bought a new position in Outlook Therapeutics during the third quarter valued at $55,000. 11.20% of the stock is owned by hedge funds and other institutional investors.

Outlook Therapeutics Price Performance

Shares of NASDAQ OTLK opened at $2.23 on Monday. The firm has a market cap of $55.55 million, a PE ratio of -0.25 and a beta of 0.53. The company has a 50 day simple moving average of $2.70 and a 200 day simple moving average of $5.33. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last posted its quarterly earnings data on Friday, December 27th. The company reported ($0.77) EPS for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.06. As a group, research analysts anticipate that Outlook Therapeutics will post -2.33 earnings per share for the current fiscal year.

About Outlook Therapeutics

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.